Home
Solutions
Products
Pricing
Resources
Request Demo
Start Free
Menu Search Account

LegiStorm

Get LegiStorm App Visit Product Demo Website
» Get LegiStorm App
» Get LegiStorm Pro Free Demo
StateStorm

Weekly Updates

LegiStorm is constantly adding new information on the people, places and reports in our database. In the past week, LegiStorm added:

  • 1456 new people
  • 43 new organizations
  • 1442 new photos
  • 1851 job history records for people in our database
  • 618 education records for people in our database
  • 2666 contact addresses, emails and URLs (LinkedIn, Facebook, etc.)
  • 2 new people through the revolving door
  • 253 new policy reports
  • 19 new trips to our privately funded travel database
  • 11431 new press releases
  • 19 new town halls

Caught Our Eye Rss

» More from Caught Our Eye
» More from our DevBlog

H.R. 2557, Prostate Cancer Misdiagnosis Elimination Act of 2017 (CBO Report for Congress)

Premium   Download PDF Now (3 pages)
Congress 115th
Date Requested Oct. 4, 2017
Requested By House Committee on Energy and Commerce
Date Sent Oct. 24, 2017
Description:

H.R. 2557 would require the Medicare program to cover a certain type of laboratory test for beneficiaries who test positive for prostate cancer. CBO estimates that H.R. 2557 would, on net, decrease direct spending by $7 million over the 2018-2027 period.

Enacting H.R. 2557 would affect direct spending; therefore, pay-as-you-go procedures apply. The legislation would not affect revenues.

CBO estimates that enacting H.R. 2557 would not increase net direct spending or on-budget deficits in any of the four consecutive 10-year periods beginning in 2028.

H.R. 2557 contains no intergovernmental or private-sector mandates as defined in the Unfunded Mandates Reform Act.

« Return to search CBO reports

HomeAbout Us Contact UsPrivacy PolicyTerms of UseJoin Us
© LegiStorm
LegiStorm
2101 L St. NW, Suite 300
Washington, DC 20037
(202) 360-4172 / congress@legistorm.com